Yes — results are overdue. Primary completion was 2018-03-29; the FDAAA-801 reporting deadline (2019-03-29) passed 2687 days ago and no results are posted on ClinicalTrials.gov.
| NCT ID | NCT02818686 ↗ |
|---|---|
| Sponsor | Theravance Biopharma (INDUSTRY) |
| Public issuer | Theravance Biopharma, Inc. — TBPH (CIK 0001583107) best-effort name match, 95% conf — verify on EDGAR ↗ |
| Phase | PHASE1 |
| Status | COMPLETED |
| Primary completion | 2018-03-29 (ACTUAL) |
| Reporting deadline | 2019-03-29 (completion + 365d) |
| Days overdue | 2687 |
| Results posted | No — check results tab ↗ |
| FDA-regulated | drug: yes, device: no |
| Provenance | Flagged overdue on 2026-06-21 · SHA-256 bdd1f294783e09cb… (hash-chained, tamper-evident) |
Source of record: ClinicalTrials.gov NCT02818686. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.